case_images: PMC6372995_01
case_images: Computed tomography findings in the former hospital. Multiple recurrent metastatic tumors (white arrows) are detected (a). The recurrent metastatic tumors (white arrows) are shrinking at the 12th month (b) and growing again at the 23rd month (c) after the chemotherapy. They are the same horizontal levels.
case_images: 10.1177_2050313X18819599-fig1.jpg
case_images: PMC6372995_01_10.1177_2050313X18819599-fig1.jpg
case_images: fig1-2050313X18819599
case_images: The computed tomography (CT) findings in the previous hospital showed some recurrent masses and metastatic tumors: 144 x 137 x 120 mm3 mass in the left abdomen to the pelvic cavity, a 50 x 43 mm2 mass on the right pelvic wall, a 52 x 47 mm2 mass on the ascending colon, and small metastatic masses on the diaphragm and bilateral lungs (Figure 1(a)). Serum CA19-9 and CA125 levels decreased dramatically to around 110 ng/mL and the normal range, respectively (Figure 2), and CT showed shrinkage of the recurrent tumors (Figure 1(b)). The CT findings indicated tumor growth (Figure 1(c)).
case_images: Changes of serum tumor marker levels (CA125 and CA19-9) during therapy: (a) the days of discontinuation and (b) restart of the therapy.
case_images: 10.1177_2050313X18819599-fig2.jpg
case_images: PMC6372995_01_10.1177_2050313X18819599-fig2.jpg
case_images: fig2-2050313X18819599
case_images: Serum CA19-9 and CA125 levels decreased dramatically to around 110 ng/mL and the normal range, respectively (Figure 2), and CT showed shrinkage of the recurrent tumors (Figure 1(b)).